GlaxoSmithKline (GSK) Upgraded at Kepler Capital Markets
GlaxoSmithKline (NYSE:GSK) was upgraded by Kepler Capital Markets from a “reduce” rating to a “hold” rating in a research report issued on Friday.
Several other brokerages have also weighed in on GSK. JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline in a research note on Tuesday, October 24th. Zacks Investment Research lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. Investec lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Monday, November 6th. TheStreet upgraded GlaxoSmithKline from a “c+” rating to a “b” rating in a research note on Wednesday, October 25th. Finally, ValuEngine lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $38.57.
Shares of GlaxoSmithKline (NYSE GSK) traded up $0.32 during mid-day trading on Friday, hitting $36.49. The stock had a trading volume of 5,870,919 shares, compared to its average volume of 5,290,000. The firm has a market cap of $90,520.00, a PE ratio of 41.94, a PEG ratio of 2.31 and a beta of 0.98. The company has a current ratio of 0.64, a quick ratio of 0.44 and a debt-to-equity ratio of 2.96. GlaxoSmithKline has a fifty-two week low of $34.52 and a fifty-two week high of $44.53.
Large investors have recently bought and sold shares of the business. Wealthcare Advisory Partners LLC increased its stake in GlaxoSmithKline by 1,982.8% during the 3rd quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock worth $143,000 after buying an additional 3,351 shares in the last quarter. Field & Main Bank purchased a new stake in GlaxoSmithKline during the 4th quarter worth approximately $132,000. First Dallas Securities Inc. purchased a new stake in GlaxoSmithKline during the 4th quarter worth approximately $142,000. Advisory Services Network LLC increased its stake in GlaxoSmithKline by 24.2% during the 2nd quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock worth $175,000 after buying an additional 788 shares in the last quarter. Finally, Waldron LP purchased a new stake in GlaxoSmithKline during the 3rd quarter worth approximately $203,000. Institutional investors own 9.66% of the company’s stock.
WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/glaxosmithkline-gsk-upgraded-at-kepler-capital-markets/1855929.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.